专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2014044758A1 NOVEL IL-17A BINDING MOLECULES AND MEDICAL USES THEREOF 审中-公开
标题翻译：新型IL-17A结合分子及其医疗用途
公开(公告)号：WO2014044758A1
公开(公告)日：2014-03-27
申请号：PCT/EP2013/069481
申请日：2013-09-19
申请人： COVAGEN AG
发明人： SILACCI MELKKO, Michela , BÄNZIGER, Nadja , WOODS, Richard , ZHA, Wenjuan , ATTINGER, Isabella , SANTIMARIA, Roger , LEMBKE, Wibke , BATEY, Sarah , VON DER BEY, Ulrike , BERTSCHINGER, Julian , GRABULOVSKI, Dragan
IPC分类号： A61K38/16 , C07K14/00 , A61P19/00
CPC分类号： C07K14/4703 , A61K38/16 , A61K38/1709 , C07K16/241 , C07K16/244 , C07K2317/92 , C07K2317/94 , C07K2318/20 , C07K2319/00 , C07K2319/30
摘要： The present invention relates to a polypeptide inhibiting the activity of glycosylated IL-17A, wherein the polypeptide comprises or consists of an amino acid sequence selected from the group consisting of: (a) GVTLFVALYDY(X 1 )(X 2 )(X 3 )(X 4 )(X 5 )(X 6 )DLSFHKGEKFQIL STHEYEDWWEARSLTTGETGYIPSNYVAPVDSIQ (SEQ ID NO: 1), wherein amino acid positions (X 1 ) to (X 6 ) may be any amino acid sequence; and (b) an amino acid sequence which is at least 85% identical to the amino acid sequence of (a), wherein the identity determination excludes amino acid positions (X 1 ) to (X 6 ) and provided that the amino acid sequence STHEYE (SEQ ID NO: 2) in amino acid positions 31 to 36 of SEQ ID NO: 1 is conserved. The invention also relates to fusion constructs, compositions and medical uses comprising said polypeptide.
摘要翻译：本发明涉及抑制糖基化IL-17A活性的多肽，其中所述多肽包含选自以下的氨基酸序列或由以下组成：（a）GVTLFVALYDY（X1）（X2）（X3）（X4）（X5）（X6）DLSFHKGEKFQIL STHEYEDWWEARSLTTGETGYIPSNYVAPVDSIQ（SEQ ID NO：1），其中氨基酸位置（X1）至（X6）可以是任何氨基酸序列; 和（b）与（a）的氨基酸序列至少85％相同的氨基酸序列，其中身份确定不包括氨基酸位置（X1）至（X6），并且条件是氨基酸序列STHEYE（SEQ ID NO： SEQ ID NO：1的氨基酸位置31至36中的SEQ ID NO：2）是保守的。本发明还涉及包含所述多肽的融合构建体，组合物和医学用途。

2. 发明申请

WO2011023685A1 IL-17 BINDING COMPOUNDS AND MEDICAL USES THEREOF 审中-公开
标题翻译： IL-17结合化合物及其医疗用途
公开(公告)号：WO2011023685A1
公开(公告)日：2011-03-03
申请号：PCT/EP2010/062314
申请日：2010-08-24
申请人： COVAGEN AG , GRABULOVSKI, Dragan , MELKKO, Michela Silacci , MOURLANE, Frédéric , BRACK, Simon Sebastian , BERTSCHINGER, Julian
发明人： GRABULOVSKI, Dragan , MELKKO, Michela Silacci , MOURLANE, Frédéric , BRACK, Simon Sebastian , BERTSCHINGER, Julian
IPC分类号： C07K14/435
CPC分类号： C07K14/4703 , A61K38/00 , C07K16/00 , C07K2319/00 , C07K2319/30 , C07K2319/31 , C07K2319/55 , C07K2319/70
摘要： The present invention relates to new IL-17 inhibiting polypeptides, corresponding fusion proteins, compositions and medical uses thereof.
摘要翻译：本发明涉及新的IL-17抑制多肽，相应的融合蛋白，组合物和医疗用途。

3. 发明申请

WO2019068633A1 CD3/CD33 BISPECIFIC BINDING MOLECULES 审中-公开
公开(公告)号：WO2019068633A1
公开(公告)日：2019-04-11
申请号：PCT/EP2018/076634
申请日：2018-10-01
申请人： COVAGEN AG
发明人： BRACK, Simon, Sebastian , KLUPSCH, Kristina , ATTINGER-TOLLER, Isabella , BULLER, Fabian , ZUMSTEG, Adrian , BERTSCHINGER, Julian , GRABULOVSKI, Dragan , BAERISWYL, Vanessa , ROQUETTE, Joana , SCHOLZ, Roland , SANTIMARIA, Roger , SENN, David , KAGE, Elena , ALBANI, Clara
IPC分类号： C07K16/00 , C07K16/28 , C07K16/32 , A61P35/00 , A61K39/00
摘要： Advantageous bispecific binding molecules that comprise a CD3 binding and a CD33 binding part are provided. The CD3 binding part comprises an antibody that has variations in the Fc region with reduced binding to C1 q and Fc gamma receptors. The bispecific binding molecules can be used in the treatment of cancer.

4. 发明申请

WO2019068632A1 IGG1 FC MUTANTS WITH ABLATED EFFECTOR FUNCTIONS 审中-公开
公开(公告)号：WO2019068632A1
公开(公告)日：2019-04-11
申请号：PCT/EP2018/076631
申请日：2018-10-01
申请人： COVAGEN AG
发明人： BRACK, Simon, Sebastian , ATTINGER-TOLLER, Isabella , BULLER, Fabian , GRABULOVSKI, Dragan , BERTSCHINGER, Julian , ZUMSTEG, Adrian
IPC分类号： C07K16/28 , C07K16/32
摘要： Antibody and other Fc-containing molecules with variations in the Fc region with reduced binding to C1q and Fc gamma receptors are provided, which can be used in the treatment of various diseases and disorders.

5. 发明申请

WO2018185050A1 FGFR3 BINDING MOLECULES 审中-公开
公开(公告)号：WO2018185050A1
公开(公告)日：2018-10-11
申请号：PCT/EP2018/058390
申请日：2018-04-03
申请人： COVAGEN AG
发明人： SILACCI MELKKO, Michaela , WOODS, Richard , HENNE, Patricia , ZUBLER, Barbara , KAGE, Elena , GRABULOVSKI, Dragan , BERTSCHINGER, Julian
IPC分类号： C07K16/28 , C07K14/705
摘要： The present invention relates to a polypeptide binding to fibroblast growth factor receptor 3 iso forms 3b and 3c (FGFR3b and FGFR3c), wherein the polypeptide comprises an amino acid sequence selected from the group consisting of: (a) GVTLFVALYDYEVYGPTPMLSFHKGEKFQIL(X 1 )(X 2 )(X 3 ) (X 4 )GPYWEARSL(X 5 )TGETG(X 6 )IPSNYVAPVDSIQ (SEQ ID NO: 1), wherein amino acid positions (X 1 ) to (X 6 ) may be any amino acid sequence; (b) an amino acid sequence which is at least 95% identical to the amino acid sequence of (a), wherein the identity determination excludes amino acid positions (X 1 ) to (X 6 ) and provided that the amino acid sequence EVYGPTPM (SEQ ID NO: 2) in amino acid positions 12 to 19 of SEQ ID NO: 1 is conserved and the amino acids P and Y in amino acid positions 37 and 38 of SEQ ID NO: 1 are conserved; (c) GVTLFVALYDYEVMSTTALSFHKGEKF QILSQSPHGQYWEARSLTTGETG(X 6 )IPSNYVAPVDSIQ (SEQ ID NO: 19), wherein the amino acid position (X 6 ) may be any amino acid; and (d) an amino acid sequence which is at least 95% identical to the amino acid sequence of (c), wherein the identity determination excludes amino acid position (X 6 ) and provided that the amino acid sequences EVMSTTA (SEQ ID NO: 20) in amino acid positions 12 to 18 of SEQ ID NO: 19 and SQSPH (SEQ ID NO: 21) in amino acid positions 31 to 35 of SEQ ID NO: 19 are conserved and the amino acids Q and Y in amino acid positions 37 and 38 of SEQ ID NO: 19 are conserved.

6. 发明申请

WO2014106583A1 HUMAN SERUM ALBUMIN BINDING COMPOUNDS AND FUSION PROTEINS THEREOF 审中-公开
标题翻译：人血清白蛋白结合物及其融合蛋白
公开(公告)号：WO2014106583A1
公开(公告)日：2014-07-10
申请号：PCT/EP2013/077227
申请日：2013-12-18
申请人： COVAGEN AG
发明人： BULLER, Fabian , WÜLLNER, Ulrich , ZBINDEN, Irene , ATTINGER-TOLLER, Isabella , VON DER BEY, Ulrike , KÖNIG-FRIEDRICH, Susann , BERTSCHINGER, Julian , GRABULOVSKI, Dragan , HENNE, Patricia
IPC分类号： C07K14/765 , C07K14/47 , C12N1/21 , C12N1/15 , C12N5/10
CPC分类号： C12N9/12 , C07K14/47 , C07K14/765 , C07K16/18 , C07K2317/31 , C07K2319/31 , C12Y207/10002
摘要： The present invention relates to a polypeptide binding to human serum albumin and comprising or consisting of an amino acid sequence selected from the group consisting of: (a) GVTLFVALYDY(X 1 )(X 2 )(X 3 )(X 4 )(X 5 )(X 6 )D(X 7 )SFHKGEKFQIL(X 8 )(X 9 )(X 10 )(X 11 )(X 12 )G(X 13 )(X 14 )W(X 15 )(X 16 )RSLTTG(X 17 )(X 18 )G(X 19 )IPSNYVAPVDSIQ (SEQ ID NO: 1 ), wherein (X 1 ) is A, V, I, L, M, G, P, S, T, N, Q, C, R, H, K, D or E; (X 2 ) is R, H, K, A, V, I, L, M, G, P, S, T, N, Q or C; (X 3 ) is R, H, K, S, T, N, Q, C, F, Y, W, A, V, I, L, M, G or P; (X 4 ) is S, T, N, Q, C, A, V, I, L, M, G, P, R, H, K, F, Y, W, D or E; (X 5 ) is S, T, N, Q, C, D, E, F, Y, W, A, V, I, L, M, G, P, R, H or K; (X 6 ) is F, Y, W, A, V, I, L, M, G, P, R, H, K, S, T, N, Q or C; (X 7 ) is A, V, I, L, M, G, P, R, H or K; (X 8 ) is S, T, N, Q, C, D or E; (X 9 ) is S, T, N, Q, C, D, E, A, V, I, L, M, G, P, F, Y or W; (X 10 ) is A, V, I, L, M, G or P; (X 11 ) is F, Y, W, R, H or K; (X 12 ) is S, T, N, Q, C, F, Y or W; (X 13 ) is F, Y, W, R, H, K, S, T, N, Q, C, D, E, A, V, I, L, M, G or P; (X 14 ) is F, Y, W, A, V, I, L, M, G or P; (X 15 ) is D, E, A, V, I, L, M, G or P; (X 16 ) is A, V, I, L, M, G or P; (X 17 ) is D, E, A, V, I, L, M, G, P, R, H or K; (X 18 ) is S, T, N, Q, C, A, V, I, L, M, G or P; (X 19 ) is F, Y, W, S, T, N, Q or C; and (b) an amino acid sequence which is at least 90% identical to the amino acid sequence of (a), wherein the identity determination excludes amino acid positions (X 1 ) to (X 19 ).
摘要翻译：本发明涉及与人血清白蛋白结合的多肽，其含有选自：（a）GVTLFVALYDY（X1）（X2）（X3）（X4）（X5）（X6） D（X7）（X9）（X9）（X9）（X10）（X11）（X12）G（X13）（X14）W（X15）（X16）RSLTTG（X17）（X18）G（X19）IPSNYVAPVDSIQ（SEQ ID NO ：1）其中（X1）为A，V，I，L，M，G，P，S，T，N，Q，C，R，H，K，D或E; （X2）为R，H，K，A，V，I，L，M，G，P，S，T，N，Q或C; （X3）为R，H，K，S，T，N，Q，C，F，Y，W，A，V，I，L，M，G或P; （X4）是S，T，N，Q，C，A，V，I，L，M，G，P，R，H，K，F，Y，W，D或E; （X5）是S，T，N，Q，C，D，E，F，Y，W，A，V，I，L，M，G，P，R，H或K; （X6）为F，Y，W，A，V，I，L，M，G，P，R，H，K，S，T，N，Q或C; （X7）为A，V，I，L，M，G，P，R，H或K; （X8）为S，T，N，Q，C，D或E; （X9）是S，T，N，Q，C，D，E，A，V，I，L，M，G，P，F，Y或W; （X10）为A，V，I，L，M，G或P; （X11）为F，Y，W，R，H或K; （X12）为S，T，N，Q，C，F，Y或W; （X13）为F，Y，W，R，H，K，S，T，N，Q，C，D，E，A，V，I，L，M，G或P; （X14）为F，Y，W，A，V，I，L，M，G或P; （X15）为D，E，A，V，I，L，M，G或P; （X16）为A，V，I，L，M，G或P; （X17）为D，E，A，V，I，L，M，G，P，R，H或K; （X18）为S，T，N，Q，C，A，V，I，L，M，G或P; （X19）为F，Y，W，S，T，N，Q或C; 和（b）与（a）的氨基酸序列至少90％相同的氨基酸序列，其中身份确定不包括氨基酸位置（X1）至（X19）。

7. 发明申请

WO2014170063A1 NOVEL BISPECIFIC BINDING MOLECULES WITH ANTITUMORAL ACTIVITY 审中-公开
标题翻译：具有抗肿瘤活性的新型双重结合分子
公开(公告)号：WO2014170063A1
公开(公告)日：2014-10-23
申请号：PCT/EP2014/054390
申请日：2014-03-06
申请人： COVAGEN AG
发明人： BULLER, Fabian , WÜLLNER, Ulrich , KLUPSCH, Kristina , ZBINDEN, Irene , SANTIMARIA, Roger , ATTINGER-TOLLER, Isabella , KÖNIG-FRIEDRICH, Susann , BERTSCHINGER, Julian , GRABULOVSKI, Dragan , BRACK, Simon , SILACCI, Michela , WOODS, Richard , HACHEMI, Helen , HENNE, Patricia , VON DER BEY, Ulrike
IPC分类号： C07K14/47 , C07K16/28 , C07K16/46
CPC分类号： C12Y207/10002 , A61K2039/505 , C07K16/2809 , C07K16/2851 , C07K16/2863 , C07K16/32 , C07K2317/31 , C07K2317/73 , C07K2318/20 , C07K2319/33
摘要： The present invention relates to a bispecific binding molecule that specifically binds to (i) CD3 and (ii) a surface target antigen on cancer cells, wherein the binding molecule comprises (a) an antibody specifically binding to CD3, and (b) a Fyn-SH3-derived polypeptide binding to a surface target antigen on cancer cells, wherein said Fyn-SH3-derived polypeptide consists of the amino acid sequence of SEQ ID NO: 1, with the proviso that (i) at least one amino acid within amino acids positions 10 to 19 of SEQ ID NO: 1 is substituted, deleted or added, and (ii) at least one amino acid amino acid within amino acids positions 29 to 36 of SEQ ID NO: 1 is substituted, deleted or added, provided that said polypeptide has at least 85% sequence identity to the amino acid sequence of SEQ ID NO: 1, wherein the determination of identity excludes amino acid positions 12 to 17 and 31 to 34 of SEQ ID NO: 1.
摘要翻译：本发明涉及特异性结合（i）CD3和（ii）癌细胞上的表面靶抗原的双特异性结合分子，其中结合分子包含（a）特异性结合CD3的抗体，和（b）Fyn -SH3衍生的多肽与癌细胞上的表面靶抗原结合，其中所述Fyn-SH3衍生的多肽由SEQ ID NO：1的氨基酸序列组成，条件是（i）氨基酸内的至少一个氨基酸取代，缺失或加入SEQ ID NO：1的10至19位的氨基酸，并且（ii）SEQ ID NO：1的氨基酸位置29至36中的至少一个氨基酸氨基酸被替代，缺失或添加所述多肽与SEQ ID NO：1的氨基酸序列具有至少85％的序列同一性，其中同一性的确定排除了SEQ ID NO：1的氨基酸位置12至17和31至34。

8. 发明申请

WO2013135588A1 NOVEL BINDING MOLECULES WITH ANTITUMORAL ACTIVITY 审中-公开
标题翻译：具有抗肿瘤活性的新型结合分子
公开(公告)号：WO2013135588A1
公开(公告)日：2013-09-19
申请号：PCT/EP2013/054768
申请日：2013-03-08
申请人： COVAGEN AG
发明人： BRACK, Simon , MOURLANE, Frédéric , TOLLER, Isabella , WOODS, Richard , BERTSCHINGER, Julian , GRABULOVSKI, Dragan , SCHADE, Babette , KLUPSCH, Kristina , HACHEMI, Helen
IPC分类号： A61K39/395 , C07K16/32 , A61P35/00
CPC分类号： C12N9/12 , A01K67/0278 , A01K2227/105 , A01K2267/01 , A61K39/39591 , A61K2039/505 , C07K16/30 , C07K16/32 , C07K2317/31 , C07K2317/73 , C07K2317/77 , C07K2317/90 , C07K2318/20 , C07K2319/00 , C07K2319/30 , C12Y207/10002
摘要： The present invention relates to a binding molecule that specifically binds to two different epitopes of an antigen expressed on tumor cells, wherein the binding molecule comprises: (a) a first binding (poly)peptide that specifically binds to a first epitope of said antigen expressed on tumor cells, wherein said first binding (poly)peptide is a Fyn SH3-derived polypeptide; and (b) a second binding (poly)peptide that specifically binds to a second epitope of said antigen expressed on tumor cells. The present invention further relates to a nucleic acid molecule encoding the binding molecule of the invention, a vector comprising said nucleic acid molecule as well as a host cell or a non-human host transformed with said vector. The invention further relates to a method of producing a binding molecule of the invention as well as to pharmaceutical and diagnostic composition. Moreover, the present invention also relates to the binding molecule, the nucleic acid molecule, the vector or the host cell of the invention for use in the treatment of tumors.
摘要翻译：本发明涉及特异性结合在肿瘤细胞上表达的抗原的两个不同表位的结合分子，其中所述结合分子包含：（a）特异性结合表达的所述抗原的第一表位的第一结合（多）肽其中所述第一结合（多）肽是衍生自Fyn SH3的多肽; 和（b）特异性结合在肿瘤细胞上表达的所述抗原的第二表位的第二结合（多）肽。本发明还涉及编码本发明的结合分子的核酸分子，包含所述核酸分子的载体以及用所述载体转化的宿主细胞或非人宿主。本发明还涉及制备本发明的结合分子以及药物和诊断组合物的方法。此外，本发明还涉及用于治疗肿瘤的本发明的结合分子，核酸分子，载体或宿主细胞。

9. 发明申请

WO2012159836A1 NEW CHYMASE BINDING COMPOUNDS AND MEDICAL USES THEREOF 审中-公开
标题翻译：新型化合物结合物及其医疗用途
公开(公告)号：WO2012159836A1
公开(公告)日：2012-11-29
申请号：PCT/EP2012/057489
申请日：2012-04-24
申请人： COVAGEN AG , BRACK, Simon , BATEY, Sarah , GRABULOVSKI, Dragan , BERTSCHINGER, Julian , SCHLATTER, Daniel , BENZ, Jörg , BANNER, David , HENNIG, Michael
发明人： BRACK, Simon , BATEY, Sarah , GRABULOVSKI, Dragan , BERTSCHINGER, Julian , SCHLATTER, Daniel , BENZ, Jörg , BANNER, David , HENNIG, Michael
IPC分类号： C07K14/47 , C12N9/12
CPC分类号： C12N9/12 , C07K14/4703 , C12N9/1205 , G01N33/573
摘要： The present invention relates to a polypeptide binding to a chymase (EC 3.4.21.39), wherein the polypeptide comprises or consists of an amino acid sequence selected from the group consisting of: (a) GVTLFVALYDY(X 1 )A(X 2 )(X 3 )(X 4 )(X 5 )(X 6 )LSFHKGEKFQIL(X 7 )(X 8 )(X 9 )(X 10 ) (X 11 )(X 12 )G(X 13 )(X 14 )WEARSLTTGETGYIPSNYVAPVDSIQ (SEQ ID NO: 1), wherein (X 1 ) is R, N, Q, E, K, H, S, T, C, or D; (X 2 ) is E, T, D, Q, L, P, A, S, C, M, N, E, G, A, V or I; (X 3 ) is R, T, H, N, K, S, C, N or Q; (X 4 ) is S, W, T, C, N, Q, F or Y; (X 5 ) is T, H, L, F, C, S, M, N, Q, R, K, G, A, V, I, P, Y or W; (X 6 ) is D, Q, H, E, S, T, C, N, R or K; (X 7 ) is D, N, R, E, Q, S, T, C, K or D; (X 8 ) is M, W, G, F, A, S, T, C, S, N, Q, Y, V, L, I or P; (X 9 ) is T, H, S, D, C, N, Q, R, K, E or absent; (X 10 ) is V, T, Q, G, A, L, I, P, S, C, M, N or absent; (X 11 ) is P, A, D, G, K, V, L, I, E, R, M, H or absent; (X 12 ) is N, V, P, I, E, T, S, A, G, L, C, M, Q or D; (X 13 ) is D, E, T, P, G, A, V, L, I, S, C, M, N or Q, and (X 14 ) is W, Y, L, G, A, V, I, P, M, or F; (b) an amino acid sequence which is at least 85% identical to the amino acid sequence of (a), wherein the identity determination excludes amino acid positions (X 1 ) to (X 14 ).
摘要翻译：本发明涉及与胃促胰酶（EC 3.4.21.39）结合的多肽，其中所述多肽包含选自以下的氨基酸序列或由以下组成：（a）GVTLFVALYDY（X1）A（X2）（X3）（X4）（X5）（X6）（X7）（X8）（X9）（X10）（X11）（X12）G（X13）（X14）WEARSLTGG ，N，Q，E，K，H，S，T，C或D; （X2）是E，T，D，Q，L，P，A，S，C，M，N，E，G，A，V或I; （X3）为R，T，H，N，K，S，C，N或Q; （X4）为S，W，T，C，N，Q，F或Y; （X5）是T，H，L，F，C，S，M，N，Q，R，K，G，A，V，I，P，Y或W; （X6）为D，Q，H，E，S，T，C，N，R或K; （X7）为D，N，R，E，Q，S，T，C，K或D; （X8）为M，W，G，F，A，S，T，C，S，N，Q，Y，V，L，I或P; （X9）为T，H，S，D，C，N，Q，R，K，E或不存在; （X10）为V，T，Q，G，A，L，I，P，S，C，M，N或不存在; （X11）为P，A，D，G，K，V，L，I，E，R，M，H或不存在; （X12）为N，V，P，I，E，T，S，A，G，L，C，M，Q或D; （X13）是D，E，T，P，G，A，V，L，I，S，C，M，N或Q，（X14）是W，Y，L，G，A，V，I ，P，M或F; （b）与（a）的氨基酸序列至少85％相同的氨基酸序列，其中所述身份确定不包括氨基酸位置（X1）至（X14）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式